At Aplos Analytics, we believe the future of pharmacokinetics (PK) should be faster, smarter, and more intuitive. In a recent interview with Bioanalysis Zone, our Founder and President, Nathan Teuscher, shared his insights on how Aplos NCA is reshaping the way scientists approach non-compartmental analysis (NCA), and why this transformation is long overdue.
For decades, PK scientists have relied on legacy tools that were originally designed in a very different era of drug development. These platforms often require programming knowledge, manual file handling, and time-consuming formatting. As Nathan explains in the interview, this legacy approach not only creates inefficiencies but also increases the risk of inconsistencies and delays in reporting.
“Pharmacokinetics is a mature science,” Nathan says, “but our tools haven't evolved as quickly as the rest of the drug development ecosystem. We saw a real need for a platform that is simple to use, built for collaboration, and designed to automate the repetitive parts of the workflow without sacrificing scientific rigour.”
Aplos NCA is designed with modern scientists in mind. Nathan emphasises that one of the platform’s greatest strengths is its intuitive interface, built to be used without coding or scripting. That means faster onboarding, less time spent training teams, and more time devoted to high-impact scientific analysis.
“We’ve focused on making sure that the software is something a scientist can use without needing a developer or a statistician next to them,” Nathan explains. “It’s plug-and-play, but still powerful and flexible.”
Automation is often associated with a trade-off in quality or transparency, but Nathan challenges that notion. Aplos NCA was built to reduce human error, ensure repeatability, and maintain compliance from day one. Every output is generated from fully auditable workflows, and scientists can define their own templates and reporting formats for submission-ready results.
As Nathan puts it: “Automation doesn’t mean losing control, it means gaining confidence in your analysis.”
Looking ahead, Nathan shares that Aplos is continuing to expand its capabilities beyond single-dose studies, with support for steady-state and more complex designs already in place. The team is also investing in enhanced reporting features and integrations that make it easier to scale across global teams and CRO partners.
“We’re not here to replace scientists,” Nathan concludes. “We’re here to remove the friction, so scientists can focus on the parts of their work that really matter.”
Want to learn more?
Explore the full interview with Nathan Teuscher on Bioanalysis Zone:
Read the full article
Or try Aplos NCA for yourself, and experience the next generation of PK analysis. Contact us: info@aplosanalytics.com